Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Hampson Industries, Bezant, Tangent Comms...

Thu, 26th Nov 2009 14:45

Aerospace and engineering group Hampson Industries reported a 32% slump in first half profit before tax to £11m on revenue down 12% to £97m."Although the immediate outlook for our core markets remains uncertain, present customer indications and the scale of new work in the pipeline all point to a gradual increase in the release of new orders in the months ahead," said chairman Chris Geoghegan."Tooling order books have increased in September and October and with leading indicators now generally more encouraging, we are cautiously optimistic of seeing further order strengthening over the second half."Gold and copper explorer Bezant lost £1.77m in the year ended 30 June 2009 due to its exploration activities in the Philippines and Tanzania.Executive chairman Gerry Nealon says Bezant's flagship Mankayan project in the Philippines has the potential to become a world class mine. News on future plans are expected early next yearPre-tax profit fell to £189,000 at Tangent Communications in the six months to 31 August, down from £500,000 in 2008, although the direct marketing firm says the outlook for the rest of the year is in line with management's expectations."The increased cost base from our recent acquisitions had a negative impact on the overall profitability, although we expect this investment in skills to deliver future growth in higher margin parts of the business," said the group.Stem cell developer ReNeuron narrowed losses from £3m to £2m in the year to September and said it has secured a two-year equity funding facility up to £5m from its joint broker, Matrix Corporate Capital.The AIM-listed firm said it remains confident of meeting the remaining requirements for its pioneering ReN001 therapy for stroke to allow initiation of a first-in-man clinical trial early next year.Alexon Group, the ladies clothing retailer, reports total sales for the 16 weeks to 21 November dropped 14% on a like for like basis.The firm blamed a 16.9% slump in sales for the first 8 weeks of the period on its decision to make fewer summer reductions, although they fell just 8.7% in the final 8 weeks. "Looking ahead, the board anticipates that the current price competitive environment will continue through the critical Christmas trading period and into the January sales. This is likely to adversely affect margins but the company's financial position remains secure," it said.
More News
29 Nov 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
23 Oct 2019 15:50

ReNeuron presents new data on CTX stem cell platform

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Wednesday that new data relating to its CTX stem cell platform was being presented at the 27th Annual Congress of the European Society of Gene and Cell Therapy in Barcelona.

Read more
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.